We are live on
!
Find out more
RM
RP Management Portfolio holdings
AUM
$139M
1-Year Est. Return
37.98%
This Fund
S&P 500
This Quarter
Est. Return
+22.74%
1 Year Est. Return
-37.98%
3 Year Est. Return
+207.8%
5 Year Est. Return
+1,098.05%
10 Year Est. Return
–
AUM
$205M
AUM Growth
-$61.3M
(-23%)
Cap. Flow
-$102M
Cap. Flow
% of AUM
-49.5%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
1
Reduced
1
Closed
1
Avg Time Held Equity + Options
8
quarters
Top 10 Avg Time Held Equity + Options
8
quarters
Top 20 Avg Time Held Equity + Options
8
quarters
Avg Time Held Equity only
8.7
quarters
Top 10 Avg Time Held Equity only
8.7
quarters
Top 20 Avg Time Held Equity only
8.7
quarters
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$81.2M |
| 2 |
Cytokinetics
CYTK
|
+$20.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.76% |
| 2 | Miscellaneous | 10.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $108M | 52.6% |
1,111,111
-1,000,000
| -47% | -$81.2M |
2018 Q4
10 quarters
|
|
|
EPZM
2
DELISTED
Epizyme, Inc
EPZM
| $76.2M | 37.14% |
9,166,667
| – | – |
2019 Q4
6 quarters
|
|
|
EPZM
3
CALL
DELISTED
Epizyme, Inc
EPZM
| $21M | 10.24% |
2,527,736
+16,259
| +0.6% | +$137K |
2019 Q4
6 quarters
|
|
4
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $42K | 0.02% |
3,700
| – | – |
2018 Q4
10 quarters
|
|
|
5
Cytokinetics
CYTK
$8.73B
| – | – |
-875,656
| Closed | -$20.4M | – |
|
Similar funds
PC
LA
TP
SC
MADFP
RM
NC
GWA
RP Management's Q2 2021 Portfolio in Review
As of Q2 2021, RP Management held 5 positions worth $205M, down 23% from $266M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
RP Management withdrew a net $102M in Q2 2021, closing 1 position and reducing 1 holding. Its most notable exit was Cytokinetics, an estimated $20.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 92% a quarter earlier, followed by Miscellaneous.
- RP Management's biggest Q2 2021 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $81.2M.
- RP Management fully exited Cytokinetics in Q2 2021, selling an estimated $20.4M.
- RP Management's ten largest holdings make up 100% of its $205M portfolio in Q2 2021.
- RP Management opened 0 new positions and closed 1 in Q2 2021.
- RP Management's portfolio value fell 23% quarter-over-quarter to $205M.
Based on RP Management's 13F filing for Q2 2021, filed 12 Aug 2021.